2. Academic Validation
  3. New Developments in Dual-Labeled Molecular Imaging Agents

New Developments in Dual-Labeled Molecular Imaging Agents

  • J Nucl Med. 2019 Apr;60(4):459-465. doi: 10.2967/jnumed.118.213488.
Servando Hernandez Vargas 1,  Sukhen C Ghosh 1,  Ali Azhdarinia 2
Affiliations

Affiliations

  • 1 Brown Foundation Institute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas.
  • 2 Brown Foundation Institute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas [email protected].
PMID: 30733318 DOI: 10.2967/jnumed.118.213488
Abstract

Intraoperative detection of tumors has had a profound impact on how Cancer surgery is performed and addresses critical unmet needs in surgical oncology. Tumor deposits, margins, and residual Cancer can be imaged through the use of fluorescent contrast agents during surgical procedures to complement visual and tactile guidance. The combination of fluorescent and nuclear contrast into a multimodality agent builds on these capabilities by adding quantitative, noninvasive nuclear imaging capabilities to intraoperative imaging. This review focuses on new strategies for the development and evaluation of targeted dual-labeled molecular imaging agents while highlighting the successful first-in-human application of this technique.

Keywords

cancer surgery; dual-labeling; fluorescence-guided surgery; multimodality imaging.

Figures
Products